Ask about this productRelated genes to: PTTG2 Blocking Peptide
- Gene:
- PTTG2 NIH gene
- Name:
- pituitary tumor-transforming 2
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 4p14
- Locus Type:
- gene with protein product
- Date approved:
- 1999-02-23
- Date modifiied:
- 2016-10-25
Related products to: PTTG2 Blocking Peptide
Related articles to: PTTG2 Blocking Peptide
- Lung adenocarcinoma (LUAD) stands as a prevalent malignancy, yet its pathology remains incompletely comprehended. - Source: PubMed
Publication date: 2025/08/28
Di JinnaTian LiYan FanZhe ZhangLin CaiJingyu Liu - The aim of the present study was to determine the expression of cyclin-dependent kinase inhibitor 3 (CDKN3) as well as its clinical value in hepatocellular carcinoma (HCC) using bioinformatic analysis. The expression of CDKN3 in HCC and its correlation with HCC prognosis were analyzed using the UALCAN and SangerBox databases. The findings obtained from the UALCAN database were validated using immunohistochemistry. The Assistant for Clinical Bioinformatics database was employed for the unifactorial and multifactorial analyses regarding the correlation between CDKN3 and pathways, and the STRING database served for the correlation analysis between CDKN3 and proteins. The results revealed that CDKN3 expression increases in tumor tissues and corresponds with an increase in the tumor stage. CDKN3 crucially affects prognosis of patients with HCC and is an essential factor for the diagnosis and prognosis of this condition. CDKN3 expression in HCC is mainly related to pathways for DNA repair, fatty acid degradation, G2M checkpoints, MYC targets, selenium compound metabolism and tumor proliferation. The role of CDKN3 in HCC was found to be related to genes including , , , and . In conclusion, CDKN3 exhibits a high expression in HCC tumor tissues, and such expression substantially affects tumor patients' prognosis. The role of CDKN3 role in HCC is closely related to cell cycle-related pathways, showing its potential as a therapeutic target for HCC and as an indicator for the determination of prognosis. - Source: PubMed
Publication date: 2025/05/22
Liu XingChang KaiyuanLiu Jian - Lung adenocarcinoma (LUAD) is a prevalent form of non-small cell lung cancer with high morbidity and mortality rates. Identifying molecular markers and therapeutic targets is crucial for improving LUAD diagnosis and treatment. Pituitary tumor-transforming gene (PTTG) family members, PTTG1, PTTG2, and PTTG3P, have been linked to several malignancies; however, it is unclear how these genes relate to LUAD. The current retrospective study investigates the diagnostic, prognostic, and therapeutic importance of PTTG genes in LUAD. - Source: PubMed
Publication date: 2024/11/15
Xu JiajiaLou XuepingLi FeiSong BiyingZheng YitingZhu JieZheng Zhencang - Osteosarcoma (OS) poses a significant clinical challenge, necessitating a comprehensive exploration of its molecular underpinnings. - Source: PubMed
Publication date: 2024/07/30
Lu YulinWang DanjunChen GuoaoShan ZitongLi Dongmei - Pituitary tumor transforming genes (PTTG1, PTTG2, and PTTG3P) play key roles in the pathogenesis and development of human cancers. The studies show that overexpression of the PTTG genes is associated with tumor progression and migration. However, the function of the PTTG genes in the prognostic value of kidney renal clear cell carcinoma is rarely known by people. - Source: PubMed
Publication date: 2021/04/12
Gui YonghuiLiu XueniWang ChaoYang Peng